Shots: The approval is based on a P-III study that evaluates Invega hafyera (q6mos., twice-yearly injectable) vs Invega trinza in 702 adults in a ratio (2:1) aged 18-70yrs. with schizophrenia […]readmore
Tags : paliperidone palmitate
Shots: The P-IIIb ALPINE Study involves assessing of Aristada and Invega Sustenna in 200 patients experiencing an acute exacerbation of schizophrenia, followed by an outpatient phase for a total of […]readmore